Evidence map›Paper›PMID 22032234›Full record

ArticleBiochemistry2011

NMR studies reveal an unexpected binding site for a redox inhibitor of AP endonuclease 1.

Brittney A Manvilla, Orrette Wauchope, Katherine L Seley-Radtke, Alexander C Drohat

Abstract read
In one paragraph

Article in Biochemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Human apurinic/apyrimidinic endonuclease 1.Antioxidants & redox signaling · 2014
    Review
  10. Structure of human apurinic/apyrimidinic endonuclease 1 with the essential Mg2+ cofactor.Acta crystallographica. Section D, Biological crystallography · 2013
    Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Brittney A ManvillaDepartment of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, Maryland 21201, United States.
Orrette Wauchope
Katherine L Seley-Radtke
Alexander C Drohat
University of Maryland, Baltimore County · USUniversity of Maryland, Baltimore · US

Funding

Structure and Mechanism of CpG specific DNA glycosylasesR01GM072711 · NIGMS · WADSWORTH CENTER · PI DROHAT, ALEX C · 2005 to 2020
$5.0M
Graduate Training at The Chemistry Biology InterfaceT32GM066706 · NIGMS · UNIVERSITY OF MARYLAND BALTIMORE COUNTY · PI SELEY-RADTKE, KATHERINE L, SMITH, AARON T · 2004 to 2023
$3.3M
NIGMS NIH HHS GM72711NIGMS NIH HHS R01 GM072711NIGMS NIH HHS T32 GM066706NIGMS NIH HHS T32-GM066706
6 · The paper itself

Abstract

AP endonuclease 1 (APE1) is a multifaceted protein with essential roles in DNA repair and transcriptional regulation. APE1 (ref-1) activates many transcription factors (TF), including AP-1 and NF-κB. While the mechanism of APE1 redox activity remains unknown, it may involve reduction of an oxidized Cys in the TF DNA-binding domain. Several small molecules inhibit APE1-mediated TF activation, including the quinone derivative E3330. It has been proposed some inhibitors bind near C65, a residue suggested to be important for TF activation, but the binding site has not been determined for any inhibitor. Remarkably, NMR and molecular docking studies here reveal E3330 binds in the DNA repair active site of APE1, far removed from C65. Accordingly, AP endonuclease activity is substantially inhibited by E3330 (100 μM), suggesting that E3330 may not selectively inhibit APE1 redox activity in cells, in contrast with previous proposals. A naphthoquinone analogue of E3330, RN7-60, binds a site removed from both C65 and the repair active site. While a detailed understanding of how these inhibitors work requires further studies into the mechanism of redox activity, our results do not support proposals that E3330 binds selectively (and slowly) to locally unfolded APE1 or that E3330 promotes formation of disulfide bonds in APE1. Rather, we suggest E3330 may suppress a conformational change needed for redox activity, disrupt productive APE1-TF binding, or block the proposed redox chaperone activity of APE1. Our results provide the first structural information for any APE1 redox inhibitor and could facilitate development of improved inhibitors for research and perhaps clinical purposes.

Indexed as

AnimalsBenzoquinonesBinding SitesDNA-(Apurinic or Apyrimidinic Site) LyaseDNA RepairEnzyme InhibitorsHumansMagnetic Resonance SpectroscopyMethacrylatesMiceNaphthoquinonesOxidation-ReductionPropionatesProtein Binding3-(3-chloro-1,4-naphthoquinon-2-yl)-2-methylpropenoic acidBenzoquinonesDNA-(Apurinic or Apyrimidinic Site) LyaseE 3330Enzyme InhibitorsMethacrylatesNaphthoquinonesPropionates

Identifiers

PMID22032234
PMCPMC3226889
OpenAlexW2052232107

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.